A panel of four immunohistochemical markers (CK7, CK20, TTF-1, and p63) allows accurate diagnosis of primary and metastatic lung carcinoma on biopsy specimens

Virchows Archiv

Volumn 463, Issue 6, 2013, Pages 749-754

  Montezuma, Diana ^a   Azevedo, Rosa ^a   Lopes, Paula ^a   Vieira, Renata ^a   Cunha, Ana Luísa ^a   Henrique, Rui ^a,b  

^a PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

Author keywords

Biopsy; Immunohistochemistry; Lung cancer; Subtyping

Indexed keywords

CK20 PROTEIN; CK7 PROTEIN; PROTEIN P63; THYROID TRANSCRIPTION FACTOR 1; TUMOR MARKER; UNCLASSIFIED DRUG; CKAP4 PROTEIN, HUMAN; CYTOKERATIN 20; CYTOKERATIN 7; DNA BINDING PROTEIN; MEMBRANE PROTEIN; TTF1 PROTEIN, HUMAN;

ADENOSQUAMOUS CARCINOMA; ARTICLE; BRONCHUS BIOPSY; CANCER DIAGNOSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; GOLD STANDARD; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG BIOPSY; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; PREDICTIVE VALUE; PRIMARY TUMOR; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TUMOR BIOPSY; CARCINOMA; CLASSIFICATION; DIAGNOSTIC USE; LUNG NEOPLASMS; METABOLISM; NEOPLASM METASTASIS;

CARCINOMA; DNA-BINDING PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; KERATIN-20; KERATIN-7; LUNG NEOPLASMS; MEMBRANE PROTEINS; NEOPLASM METASTASIS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 84890499367     PISSN: 09456317     EISSN: 14322307     Source Type: Journal    
DOI: 10.1007/s00428-013-1488-z     Document Type: Article

References (25)

1. Boyle P, Levin B (2008) World Cancer Report 2008. International Agency for Research on Cancer, Lyon
2. Herbst RS, Heymach JV, Lippman SM (2008) Lung cancer. N Engl J Med 359:1367-1380
3. Travis WD, Brambilia E, Muller-Hermelink HK et al (2004) Pathology and genetics: tumours of the lung, pleura, thymus and heart. IARC, Lyon
4. Gressett SM, Shah SR (2009) Intricacies of bevacizumab-induced toxicities and their management. Ann Pharmacother 43(3):490-501
5. Paez JG, Jänne PA, Lee JC et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304(5676):1497-1500
6. Lindeman NI, Cagle PT, Beasley MB et al (2013) Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med 137(6):828-860
7. Aisner DL, Marshall CB (2012) Molecular pathology of non-small cell lung cancer - a practical guide. Am J Clin Pathol 138:332-346
8. Travis WD, Brambilla E, Noguchi M et al (2011) The new IASLC/ATS/ERS international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 6:244-285
9. Goldstraw P, Ball D, Jett TC et al (2011) Non-small lung cancer. Lancet 378:1727-1740
10. Warth A, Mulley T, Herpel E et al (2012) Large-scale comparative analyses of immunomarkers for diagnostic subtyping of non-small-cell lung cancer biopsies. Histopathology 61(6):1017-1025
11. Thunnissen E, Boers E, Heideman DA et al (2012) Correlation of immunohistochemical staining p63 and TTF-1 with EGFR and K-ras mutational spectrum and diagnostic reproducibility in non small cell lung carcinoma. Virchows Arch 461(6):629-638
12. Kim MJ, Shin HC, Shin KC, Ro JY (2013) Best immunohistochemical panel in distinguishing adenocarcinoma from squamous cell carcinoma of the lung: tissue microarray assay in resected lung cancer specimens. Ann Diagn Pathol 17(1):85-90
13. Ueno T, Linder S, Elmberger G (2003) Aspartatic proteinase napsin is useful marker for diagnosis of primary lung adenocarcinoma. Br J Cancer 88:1229-1233
14. Ordóñez NG (2012) A word of caution regarding napsin A expression in squamous cell carcinomas of the lung. Am J Surg Pathol 36(3):396-401
15. Travis WD, Brambilla E, Noguchi M et al (2013) Diagnosis of lung cancer in small biopsies and cytology: implications of the 2011 IASLC/ATS/ERS classification. Arch Pathol Lab Med 137(5):668-684
16. Jagirdar J (2008) Application of immunochemistry to the diagnosis of primary and metastatic carcinoma to the lung. Arch Pathol Lab Med 132(3):384-396
17. Schwartz AM, Henson DE (2007) Diagnostic surgical pathology in lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 132:78S-93S
18. Mukhopadhyay S, Katzenstein AL (2011) Subclassification of non-small lung carcinomas lacking morphologic differentiation on biopsy specimens: utility of an immunohistochemical panel containing TTF-1, napsin A, P63, and CK5/6. Am J Surg Pathol 35(1):15-25
19. Pelosi G, Rossi G, Bianchi F et al (2011) Immunohistochemistry by means of widely agreed-upon markers (cytokeratins 5/6 and 7, P63, thyroid transcription factor-1, and vimentin) on small biopsies of non-small cell lung cancer effectively parallels the corresponding profiling and eventual diagnoses on surgical specimens. J Thorac Oncol 6(6):1039-1049
20. Pelosi G, Fabbri A, Bianchi F et al (2012) ΔNP63 (p40) and thyroid transcription factor-1 immunoreactivity on small biopsies or cellblocks for typing non-small cell lung cancer: a novel two-hit, sparing-material approach. J Thorac Oncol 7(2):281-290
21. Loo PS, Thomas SC, Nicolson MC, Fyfe MN, Kerr KM (2010) Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens. J Thorac Oncol 5(4):442-447
22. Mukhopadhyay S (2012) Utility of small biopsies for diagnosis of lung nodules: doing more with less. Mod Pathol 25(Suppl 1):S43-S57
23. D'Angelo SP, Pietanza MC, Johnson ML et al (2011) Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas. J Clin Oncol 29(15):2066-2070
24. Engstrom PF, Arnoletti JP, Benson AB, et al. NCCN Clinical Practice Guidelines in Oncology: colon cancer. J Natl Compr Canc Netw. 200;7(8):778-831
25. Ettinger DS, Akerley W, Bepler G et al (2010) Non-small cell lung cancer. J Natl Compr Canc Netw 8(7):740-801